PT-141 (Vyleesi): an FDA-approved libido drug with a gray-market shadow

PT-141 is the entry on this list that breaks the frontier-tier mold: it’s a genuinely FDA-approved drug. Under the name Vyleesi (bremelanotide), it was approved in 2019 for a specific, real indication, with phase 3 trials behind it. That puts it in a different category from the peptides sold purely gray-market — and it’s exactly why it needs careful handling, because the same molecule leads a double life as “PT-141,” an online research peptide marketed for libido to men and women alike, for whom it is not approved.

The honest framing has two halves that must stay separate: what it’s approved and evidenced to do, and everything else people use it for.

What it is and what it does

Bremelanotide is a melanocortin receptor agonist. Rather than acting on blood flow the way the PDE5 inhibitors (like tadalafil) do, it works centrally — in the brain’s melanocortin system — which is why it targets desire rather than the mechanics of erection or lubrication. Interestingly, the FDA label itself notes that the precise mechanism by which it improves HSDD is not fully understood. It’s given as a subcutaneous autoinjection, on demand, at least 45 minutes before anticipated activity.

What the evidence shows — and its exact limits

For its approved indication — acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — bremelanotide has the strongest thing on this entire list: an actual FDA approval, granted on the basis of two identical phase 3, randomized, double-blind, placebo-controlled trials. That’s grade-A regulatory evidence, and it deserves to be stated plainly.

It also deserves an honest asterisk. The effect size is modest — the improvements in desire and in the distress it causes are statistically real but not dramatic — and tolerability is a genuine issue: about 40% of women experienced nausea in the trials. Repeated use can cause focal hyperpigmentation (darkened patches of skin, more common in darker skin), and each dose causes a transient rise in blood pressure and drop in heart rate. So it’s approved and effective for the right person, not a magic switch.

The label is also emphatic about who it’s not for. It is not indicated for postmenopausal women or for men. That matters enormously, because the online “PT-141” market sells it heavily to exactly those groups. Earlier-phase studies in men (for erectile dysfunction and low libido) do exist and show some signal, but bremelanotide is not FDA-approved for any male indication — so male use is off-label and investigational, grade C at best.

The safety picture and who should avoid it

Two things anchor the safety conversation:

• It’s contraindicated in uncontrolled hypertension or known cardiovascular disease. The transient blood-pressure increase after each dose makes this non-negotiable — this is the main reason it belongs with a clinician, not a website.
• Nausea is common and hyperpigmentation is possible. These are the practical reasons many people who try it don’t continue.

Anyone considering it should have their blood pressure and cardiovascular risk assessed first, and should understand it’s an as-needed drug with a real side-effect profile, not a daily supplement.

The honest bottom line

For its approved job — HSDD in premenopausal women — bremelanotide (Vyleesi) is a legitimate, FDA-approved prescription with real trials, a modest effect, and a tolerability cost worth weighing. If you’re in that group, it’s a reasonable clinician conversation, mainly to confirm the diagnosis and rule out the cardiovascular contraindication. For everyone else — men, postmenopausal women, or anyone buying “PT-141” vials online — the story flips: that use is unapproved, less evidenced, and sold gray-market with unverified purity. The approval is real; it just doesn’t extend to the way most people are buying and using this peptide. Take the approved path for the approved use, and treat the rest as the open, off-label question it is.